Variables | Model with No. Flares in Last Yr | Model with Patient-reported Disease Activity |
---|---|---|
Sex, female is ref. | 1.37 (0.92–2.04) | 1.37 (0.93–2.04) |
Age at enrollment, yrs, < 65 is ref. | 1.19 (0.87–1.63) | 1.18 (0.87–1.62) |
Marital status, single is ref. | ||
Married/partnered | 1.51 (0.93–2.47) | 1.41 (0.87–2.28) |
Other | 1.74 (0.97–3.11) | 1.64 (0.92–2.90) |
Yrs of gout, > 1 vs ≤ 1 ref. | 1.84 (1.14–2.96) | 2.18 (1.37–3.47) |
Hospitalization last 3 yrs, yes vs no ref. | 1.10 (0.38–3.23) | 1.01 (0.34–2.99) |
SU at first visit, ≥ 6 vs < 6 ref. | 1.48 (1.08–2.04) | 1.47 (1.07–2.01) |
Urate-lowering drug, mg, dose* | ||
Allopurinol 50–200 | 0.62 (0.36–1.04) | 0.64 (0.39–1.07) |
Allopurinol > 200–300 | 0.64 (0.39–1.04) | 0.65 (0.40–1.05) |
Allopurinol > 300 | 0.77 (0.42–1.42) | 0.76 (0.41–1.39) |
Febuxostat 40 | 1.27 (0.66–2.43) | 1.28 (0.67–2.43) |
Febuxostat 80/other | 1.15 (0.59–2.23) | 1.08 (0.56–2.09) |
Presence of tophi, yes vs no ref. | 1.96 (1.36–2.84) | 1.91 (1.32–2.75) |
No. flares in last yr, > 1 vs ≤ 1 ref. | 2.00 (1.46–2.75) | — |
Patient-reported disease activity, > 10 vs ≤ 9 ref. | — | 1.33 (1.33–2.48) |
↵* Allopurinol or febuxostat (not receiving either drug is ref.). AOR: adjusted OR; ref.: reference.